» Articles » PMID: 38004512

Development of a Novel In Vitro Model to Study Lymphatic Uptake of Drugs Via Artificial Chylomicrons

Overview
Journal Pharmaceutics
Publisher MDPI
Date 2023 Nov 25
PMID 38004512
Authors
Affiliations
Soon will be listed here.
Abstract

The lymphatic system plays a crucial role in the absorption of lipophilic drugs, making it an important route for drug delivery. In this study, an in vitro model using Intralipid was developed to investigate the lymphatic uptake of drugs. The model was validated using cannabidiol, halofantrine, quercetin, and rifampicin. Remarkably, the uptake of these drugs closely mirrored what would transpire in vivo. Furthermore, adding peanut oil to the model system significantly increased the lymphatic uptake of rifampicin, consistent with meals containing fat stimulating lymphatic drug uptake. Conversely, the inclusion of pluronic L-81 was observed to inhibit the lymphatic uptake of rifampicin in the model. This in vitro model emerges as a valuable tool for investigating and predicting drug uptake via the lymphatic system. It marks the first phase in developing a physiologically based predictive tool that can be refined further to enhance the precision of drug interaction predictions with chylomicrons and their subsequent transport via the lymphatic system. Moreover, it can be employed to explore innovative drug formulations and excipients that either enhance or hinder lymphatic drug uptake. The insights gained from this study have significant implications for advancing drug delivery through the lymphatic system.

Citing Articles

Novel First-Generation Dissolution Models to Investigate the Release and Uptake of Oral Lymphotropic Drug Products.

Yousef M, Park C, Chacra N, Davies N, Lobenberg R AAPS PharmSciTech. 2024; 25(6):187.

PMID: 39143365 DOI: 10.1208/s12249-024-02866-y.


Parameterization of Physiologically Based Biopharmaceutics Models: Workshop Summary Report.

Pepin X, Arora S, Borges L, Cano-Vega M, Carducci T, Chatterjee P Mol Pharm. 2024; 21(8):3697-3731.

PMID: 38946085 PMC: 11304397. DOI: 10.1021/acs.molpharmaceut.4c00526.


In Vitro Predictive Model for Intestinal Lymphatic Uptake: Exploration of Additional Enhancers and Inhibitors.

Yousef M, OCroinin C, Le T, Park C, Zuo J, Chacra N Pharmaceutics. 2024; 16(6).

PMID: 38931889 PMC: 11207518. DOI: 10.3390/pharmaceutics16060768.

References
1.
Jewell A, Brookes A, Feng W, Ashford M, Gellert P, Butler J . Distribution of a highly lipophilic drug cannabidiol into different lymph nodes following oral administration in lipidic vehicle. Eur J Pharm Biopharm. 2022; 174:29-34. DOI: 10.1016/j.ejpb.2022.03.014. View

2.
Porter C, Charman W . Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev. 2001; 50(1-2):61-80. DOI: 10.1016/s0169-409x(01)00151-x. View

3.
Suresh Managuli R, Raut S, Reddy M, Mutalik S . Targeting the intestinal lymphatic system: a versatile path for enhanced oral bioavailability of drugs. Expert Opin Drug Deliv. 2018; 15(8):787-804. DOI: 10.1080/17425247.2018.1503249. View

4.
Trevaskis N, Kaminskas L, Porter C . From sewer to saviour - targeting the lymphatic system to promote drug exposure and activity. Nat Rev Drug Discov. 2015; 14(11):781-803. DOI: 10.1038/nrd4608. View

5.
Yanez J, Wang S, Knemeyer I, Wirth M, Alton K . Intestinal lymphatic transport for drug delivery. Adv Drug Deliv Rev. 2011; 63(10-11):923-42. PMC: 7126116. DOI: 10.1016/j.addr.2011.05.019. View